This page shows the latest Lamzede news and features for those working in and with pharma, biotech and healthcare.
Chiesi already markets rare disease therapy Lamzede (velmanase alfa), which is approved by the European Medicines Agency for the treatment of patients with mild to moderate alpha-mannosidosis. ... Chiesi acquired Lamzede when it bought Zymenex in 2013
England’s cost effectiveness watchdog NICE has published draft guidance not recommending Chiesi’s enzyme replacement therapy Lamzede (velmanase alfa).
Chiesi Group’s Lamzede (velmanase alfa) has been recommended for approval in Europe, putting it on course to become the first pharmacological therapy to reach the market for Alpha-Mannosidosis (AM). ... Lamzede, which was acquired when the Italian
be joined by Lamazym/Lamzede (velmanase alfa), used as an enzyme replacement therapy for the genetic disorder alpha-mannosidosis which is currently under review in Europe.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...